Addiction Pharmacology and Ibogaine
AI-extracted · unverified · confirm at source
Pharmacist's synthesis framing ibogaine risk as manageable with screening; noribogaine QTc dose-response (16–42 ms); 18 contraindications; CYP2D6 inhibitors double exposure; fatal range 4.5–29 mg/kg
Dosing: Therapeutic: 8–31 mg/kg (observational studies); estimated safe dose 0.87 mg/kg; fatal range 4.5–29 mg/kg; noribogaine dose-ranging 60/120/180 mg (not-applicable)
Safety data present: QTC
Contraindications: Schizophrenia or bipolar disorder, Pre-existing cardiac illness, Prolonged baseline QTc interval, Liver damage and/or cirrhosis, Cerebellar dysfunction, Epilepsy or seizure disorders, Pregnancy, Dementia and organic brain disease, Advanced respiratory conditions, Electrolyte abnormalities (Mg, K), Untreated thyroid disorders, Medications known to prolong QTc interval, Medications that slow heart rates, Medications that inhibit CYP2D6, Psychotropic medications, Long-acting opioids, Concurrent opioid, cocaine, or other drug use (re-sensitisation risk), Acute alcohol or benzodiazepine withdrawal (seizure risk)